Mingyuan Buying 70 Percent Stake in Chinese MDx Firm Shanghai Yuanqi for $55M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chinese biomedical testing firm Mingyuan Medicare Development announced that its wholly own subsidiary SHMY HealthDigit Biochips has entered into an agreement to purchase 70 percent of Shanghai Yuanqi for CNY354 million ($55 million).

SHMY will pay CNY225 million in cash and issue about 327 million shares of Mingyuan stock at HK$.478 per share, totaling CNY129 million, for the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.